What eBeam4Therapy does

eBeam4Therapy (eB4T) is a European Union-funded research project, established in October 2022 as a consortium between the Weizmann Institute of Science (Rehovot, Israel) and Acceler8 Venture Builder (Mosta, Malta). The project develops laser plasma accelerator (LPA) technology to generate very high energy electrons (VHEE) in the 100-250 MeV range for radiotherapy, with the goal of producing compact, cost-effective radiotherapy equipment that fits into existing treatment rooms without infrastructure modifications and at a fraction of proton therapy cost. The technology uses intense laser pulses to accelerate electrons in a compact plasma medium, replacing the meters-long accelerating structures of conventional RF accelerators.

The project's deliverables cover beam optimization, 3D dosimetric characterization, technical and commercial feasibility demonstration, and go-to-market strategy preparation. Core scientific leadership is provided by Principal Investigator Prof. Dr. Victor Malka, with research staff covering plasma physics, laser diagnostics, beam transport, GEANT4 dose simulations, and optical/dosimetry development. Laboratory facilities were completed at Weizmann in August 2024, equipped with a vacuum chamber and a 50TW Thales laser, enabling first experimental campaigns beginning in April 2025. An emerging application in Stereotactic Arrhythmia Radioablation (STAR) for cardiac arrhythmia was announced in October 2025.

eBeam4Therapy is pre-revenue and structured as a research consortium rather than a commercial entity. Its current funding comes from a European Innovation Council grant under a 3-year project framework, and it has been selected for the EIC Tech-to-Market venture building programme to support investor readiness and commercialization planning. Target end-customers for the future product are radiation oncologists, medical physicists, and hospitals seeking compact radiotherapy solutions, with planned go-to-market through partnerships with medical device companies. The project engages stakeholders via webinars, conferences (ESTRO 2025, LPAW, VHEE23), a quarterly newsletter, and direct outreach to oncologists and radiotherapy professionals.

Name

eBeam4Therapy

Legal name

eBeam4Therapy

Website

https://ebeam4therapy.eu

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

eBeam4Therapy is a pre-revenue EU-funded research consortium (Weizmann Institute and Acceler8) developing laser plasma accelerator technology to generate very high energy electrons (100-250 MeV) for compact, cost-effective radiotherapy systems targeting hospitals and oncology professionals.

Ownership category

akta.pro rank

Product category

Radiation Therapy Equipment

NAICS

Irradiation Apparatus Manufacturing (334517), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim) (HLAHABAH)

akta.pro secondary industries

Radiation Oncology (HLAKAFAC), Radiation Dose Management & Analytics (HLACALAH), Radiation Safety, Dosimetry & Regulatory Compliance (Nuclear Medicine) (HLAIAGAJ)

Keywords

• Laser-plasma accelerators
• Very high energy electrons
• Radiotherapy equipment
• Radiation oncology
• VHEE cancer treatment

Headquarters

HQ city

Rehovot

HQ country

Israel

HQ region

Middle East

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Not yet commercial: eBeam4Therapy is currently a 3-year EU-funded research project (Phase 1) demonstrating the technological and commercial feasibility of laser-plasma accelerator technology for radiotherapy. Revenue generation is not yet active. The goal is to bring a compact and inexpensive radiotherapy instrument to the market during the next decade.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Core offering

eBeam4Therapy is developing laser-plasma accelerator (LPA) technology to generate very high energy electrons (VHEE) in the 100-250 MeV range for next-generation radiotherapy. The system is designed as a compact, cost-effective radiotherapy instrument that fits existing hospital treatment rooms, offering better tumor targeting with reduced damage to surrounding healthy tissues compared to conventional photon or particle therapy. The 3-year EU-funded project is in the demonstration and pre-validation phase, targeting oncologic radiotherapy and emerging applications such as Stereotactic Arrhythmia Radioablation (STAR).

Product overview

eBeam4Therapy (eB4T) is developing a laser plasma accelerator (LPA) technology platform to generate Very High Energy Electrons (VHEE) for radiotherapy applications. The core product consists of the LPA-VHEE system that produces 100-250 MeV electron beams using compact laser technology, offering a paradigm shift in cancer treatment. The platform enables improved tumor targeting with reduced damage to healthy tissues compared to conventional radiotherapy. The technology is being developed as both a standalone radiotherapy solution and for emerging applications in cardiac arrhythmia treatment via STAR (Stereotactic Arrhythmia Radioablation). The project is a 3-year European Union funded initiative led by Weizmann Institute of Science and Acceler8 Venture Builder.

Differentiator

Problem solved

Functional benefit

Products and services

• eBeam4Therapy (eB4T) Laser-Plasma Accelerator System A next-generation radiotherapy technology using laser plasma accelerator (LPA) technology to generate very high energy electrons (VHEE) in the 100-250 MeV range for cancer treatment. The system is designed to provide compact, cost-effective radiotherapy with improved tumor targeting and reduced damage to healthy tissues compared to conventional photon radiotherapy, targeting hospitals and healthcare facilities.
• LPA-VHEE Radiotherapy Technology Laser Plasma Accelerator (LPA) technology platform that produces Very High Energy Electrons (VHEE) for radiotherapy applications. Enables routine delivery of highly energetic electrons for treating deep-tissue tumors with sub-millimeter accuracy and percent-level shot-to-shot pointing stability. Developed for radiation oncology researchers and clinical radiotherapy teams.
• VHEE-RT (Very High Energy Electron Radiotherapy) Radiotherapy modality using very high energy electrons (100-250 MeV) for cancer treatment. Offers better tumor targeting with less damage to adjacent healthy tissues, resilience to organ motion, and compatibility with existing hospital infrastructure. Targeted at hospitals, radiation oncologists, medical physicists, and radiotherapy clinics.
• eB4T LPA-VHEE for STAR (Stereotactic Arrhythmia Radioablation) Emerging clinical application of the eB4T LPA-VHEE system for non-invasive cardiac arrhythmia treatment. Delivers 200 MeV electrons with sub-millimeter accuracy for targeting arrhythmogenic cardiac tissue, offering superior dose distribution and reduced sensitivity to tissue heterogeneities compared to conventional photon-based STAR treatments. Targeted at cardiac electrophysiologists, medical physics teams, and arrhythmia treatment centers.

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Weizmann Institute of SciencecoreStrategic or Co-development PartnerOne of the world's leading basic research institutions with 250 experimental and theoretical research groups. Houses the Department of Physics of Complex Systems laser facility and the eB4T laboratory. Prof. Victor Malka's research group leads the technical R&D work including laser-plasma accelerator development and VHEE production.
• Acceler8 Venture BuildercoreStrategic or Co-development PartnerPrivately owned venture builder specializing in commercialisation of research-based innovations from ERC, EIC and EIT funded research. Manages the commercial feasibility demonstration, investor requirements, and go-to-market strategy preparation. CEO Antti Heikkila oversees commercial work with 20+ years R&D and commercialisation experience.
• Yeda Research & DevelopmentminorImplementation/ SI/ Consulting PartnerTechnology transfer company of Weizmann Institute handling IP management and legal aspects for eBeam4Therapy. Led by Adv. Aaron Jaffe with team managing intellectual property protection and commercialization rights.
• German Cancer Research Centre (DKFZ)minorStrategic or Co-development PartnerProf. Dr. Michael Baumann, Chairman and Scientific Director, provided expert insights on radiotherapy evolution. Prof. Malka addressed the DKFZ Medical Physics Seminar. Ongoing collaboration for market validation and expert feedback.
• ENSTAminorStrategic or Co-development PartnerAcademic partner with Associate Professor Alessandro Flacco participating as guest speaker at eBeam4Therapy workshop on VHEEs.
• Intense Laser Irradiation LaboratoryminorStrategic or Co-development PartnerResearch partner with Researcher Luca Labate participating as guest speaker at eBeam4Therapy workshop, contributing expertise in laser applications.
• Institut CurieminorStrategic or Co-development PartnerMedical physics research partner with Medical Physicist Ludovic De Marzi presenting at eBeam4Therapy workshop, providing clinical perspective on radiotherapy applications.
• European STOPSTORM ConsortiumminorStrategic or Co-development Partner31-institution European consortium advancing Stereotactic Arrhythmia Radioablation (STAR) techniques. eBeam4Therapy's VHEE technology is being positioned as an enabler for next-generation STAR treatment.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Accuray: Accuray manufactures CyberKnife and TomoTherapy, both advanced radiotherapy systems designed to deliver highly conformal dose distributions. It is a direct peer competing for the same radiation oncology capex budgets and is known for pushing the boundaries of precision radiotherapy beyond conventional linacs.
• Mevion Medical Systems: Mevion develops compact proton therapy systems (MEVION S250-FIT) explicitly designed to address the cost and footprint barriers of conventional proton therapy. It is the closest direct analogue to eBeam4Therapy's value proposition of delivering particle-therapy-quality dose distributions at a fraction of the infrastructure cost.

Emerging players

• ViewRay: ViewRay pioneered MR-guided radiation therapy (MRIdian) with real-time adaptive treatment capability. It represents an emerging modality play focused on improving precision and reducing damage to healthy tissue — the same clinical problem eBeam4Therapy's VHEE approach seeks to address via a fundamentally different physics route.
• RefleXion Medical: RefleXion develops biology-guided radiotherapy (BgRT) that uses PET emissions to target tumors in real time. As an emerging-stage company pursuing a novel precision radiotherapy modality, it is structurally similar to eBeam4Therapy in stage and ambition, though based on a different technological approach.

Broad incumbents

• Elekta: Elekta is a leading manufacturer of linear accelerators (Versa HD, Elekta Unity MR-Linac) and brachytherapy systems, with deep clinical integration across radiation oncology workflows. Its MR-guided Unity platform represents the type of advanced modality eBeam4Therapy competes with for next-generation radiotherapy budgets.
• Ion Beam Applications (IBA): IBA is the world's leading provider of proton therapy systems (ProteusONE, ProteusPLUS) and operates the Dosimetry business unit for beam measurement. As the dominant proton therapy vendor and a dosimetry incumbent, IBA competes for both the particle-therapy modality share and the radiation measurement infrastructure that eBeam4Therapy targets.
• Varian (Siemens Healthineers): Varian, now part of Siemens Healthineers, is the global market leader in conventional radiotherapy linear accelerators (TrueBeam, Edge) and treatment planning software. It is the dominant incumbent whose installed base and clinical relationships eBeam4Therapy's VHEE modality would ultimately have to displace or complement.
• Hitachi (Proton Therapy): Hitachi's particle therapy division supplies compact proton and carbon-ion therapy systems globally. It is one of the established particle therapy vendors competing for next-generation radiotherapy hospital installations that eBeam4Therapy's compact VHEE platform would target.

Others

• Brainlab: Brainlab develops radiotherapy planning software, ExacTrac image-guided patient positioning, and intraoperative imaging. It is an adjacent technology provider whose software ecosystem eBeam4Therapy's hardware platform would likely integrate with in clinical workflows.
• RaySearch Laboratories: RaySearch is a leading independent supplier of treatment planning and oncology information systems (RayStation, RayCare) used across radiotherapy modalities. It is thematically adjacent — eBeam4Therapy will need a treatment planning and dosimetry software ecosystem to be clinically viable, which companies like RaySearch provide.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/ebeam4therapy
• YouTubeyoutube.com/@ebeam4therapy
• LinkedInlinkedin.com/company/ebeam4therapy

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about eBeam4Therapy